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Abstract
Aim: To determine a cost-efficient strategy for HNPCC molecular diagnostic testing. 
Methods: 138 families referred to a Regional Genetics Service had hMLH1 and hMSH2 mutation analysis. The
sensitivity and specificity of clinical selection criteria with or without immunohistochemistry (IHC) and microsatellite
instability (MSI) analysis to further refine case selection and the effect of these approaches on the cost of mutation
analysis were examined. 
Results: Clearly deleterious mutations were identified in 49/138 (35.5%) of all families tested. The most sensitive
criteria for identifying families with MMR mutations were the full Bethesda guidelines but these have poor
specificity. IHC and MSI were useful pre-screening tools. 
Conclusion: A cost-efficient approach in laboratories where IHC and/or MSI analysis are available, is to use
inclusive (non-specific) criteria to select cases, followed by IHC and then MSI. Where one or both results are
abnormal, proceed to further mutation analysis. Where MSI or IHC or tumour blocks are not available, more
restrictive clinical criteria may be more appropriate for cost-efficient case selection. 
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Introduction
Hereditary non-polyposis colorectal cancer
(HNPCC) accounts for around 2-3% of all colorectal
cancers and is an autosomal dominant cancer
predisposition syndrome caused primarily by
inactivating mutations in one of the genes involved in
DNA mismatch repair (MMR), most commonly MLH1
and MSH2 [1, 2, 3]. HNPCC is characterised clinically
by an early age of onset, a predominance of
right-sided tumours and a high frequency of
synchronous and metachronous cancers. 
It is important to diagnose HNPCC because
colonoscopic surveillance with removal of adenomas
and detection of early carcinomas reduces the
colorectal cancer (CRC) rate and overall mortality in
HNPCC mutation carriers [4]. 
DNA analysis in many diagnostic laboratories has
concentrated on the two most frequently affected genes,
hMLH1 and hMSH2. Both are moderately large genes
and mutations are scattered throughout making
mutation searching expensive. The benefits of finding
a pathogenic mutation are clear; colonoscopy
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screening can be directed towards family members at
high risk and low risk family members can be
discharged from screening. Because mutation analysis
techniques are not 100% sensitive and because HNPCC
is heterogeneous, a ”negative” result from a mutation
search is essentially unhelpful. For this reason mutation
analysis is not usually recommended in individuals with
a very low probability of carrying a mutation. Practical
methods of pre-selection before DNA analysis would
allow a reduction of mutation analysis costs without
a significant loss of sensitivity in the identification of
alterations within the MLH1 and MSH2 genes and allow
a more cost-effective implementation of genetic testing
particularly in the lower probability clinical categories
(for example isolated early onset colorectal cancer). In
the diagnostic laboratory we have examined the
feasibility of pre-selection using a range of published
clinical criteria, microsatellite instability (MSI) analysis
and immunohistochemistry (IHC) to look for loss of DNA
mismatch repair enzyme expression. 
Assessment of family pedigree is the usual method
for classifying the likelihood that a patient will have
a germline MMR gene mutation [5]. Several clinical
diagnostic criteria have been proposed to identify
families with HNPCC (Table 1). The earliest published
clinical criteria are the Amsterdam criteria initially
coined to help select families for linkage studies [6].
However, these are restrictive, identifying only a small
proportion of families with detectable mutations
because of the requirement for three first-degree
relatives with colorectal cancer and the exclusion of
extracolonic tumours [7]. The Modified Amsterdam
criteria [8], the Bethesda guidelines [9], and more
recently the Amsterdam II criteria [10] followed this as
more sensitive clinically useful criteria. The Bethesda
criteria have recently been revised [11] but for the
purposes of this analysis the original Bethesda
guidelines have been used for classification of cases. 
Microsatellite instability (MSI) has been detected in
90% of tumours with a germline MMR mutation and is
considered to be a key feature of HNPCC [12, 13].
However, MSI also occurs in at least 15% of sporadic
colorectal cancers, usually due to hypermethylation of
the promoter sequence of one of the MMR
enzyme-encoding genes, usually hMLH1 [14]. 
A reference panel of five microsatellite markers
(BAT26, BAT25, D2S123, D5S346, and D17S250) has
been standardised by the National Cancer Institute for
the screening of colorectal cancer [15]. In our study we
used only BAT26, a poly (A) tract located in the fifth
intron of MSH2, because the cost of analysis worked out
at a similar cost to IHC for the purposes of
a comparison. Also BAT26 appears to have some
advantages over many other markers as it is easy to use
and has been reported to be extremely sensitive in
detecting tumours with instability [16-18]. BAT26 alleles
show only minor size variations not exceeding two base
pairs from one cell line to another, thus seeming
monomorphic or quasi-monomorphic. In addition the
Table 1. Clinical criteria for identifying families with HNPCC
Amsterdam Three relatives with colorectal cancer (CRC), one of whom is a first-degree relative of the other two; CRC involving 
at least two generations; one or more CRC cases diagnosed before the age of 50 years.
Modified Very small families, which cannot be further expanded, can be considered as HNPCC even if only two CRCs
Amsterdam in first-degree relatives; CRC must involve at least two generations, and one or more CRC cases must be diagnosed 
before the age of 55 years. 
OR two first-degree relatives affected by CRC and the presence of a third relative with an unusual early 
onset neoplasm or endometrial cancer
Amsterdam II Three relatives with an HNPCC-associated tumour (CRC, endometrial, small bowel, ureter or renal pelvis), 
one of whom is the first-degree relative of the other two; involving at least two generations; 
one or more cases diagnosed before the age of 50 years.
Bethesda 1 – Subjects with cancer in families that fulfil the Amsterdam criteria.
2 – Subjects with two HNPCC-related cancers, including synchronous and metachronous CRCs or associated extracolonic
cancers.
3 – Subjects with CRC and a first-degree relative with CRC and/or HNPCC-related extracolonic cancers and/or colorectal
adenoma(s); one of the cancers diagnosed at age <45 years and the adenoma(s) diagnosed at age <40 years.
4 – Subjects with CRC or endometrial cancer diagnosed at age <45 years.
5 – Subjects with right-sided CRC with an undifferentiated pattern (solid/cribriform) on histopathology diagnosed at age
<45 years.
6 – Subjects with signet ring cell type CRC diagnosed at age <45 years.
7 – Subjects with colorectal adenoma(s) diagnosed at age <40 years.
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Fig. 1. IHC using antibodies to MSH2 (a) and MLH1 (b) 
stability of BAT26 in the Caucasian population where any
polymorphism is rare potentially allows the determination
of tumoural microsatellite instability without reference to
germline DNA. This approach was therefore chosen as
it could potentially be set up routinely in any diagnostic
pathology laboratory for pre-screening for example all
colorectal cancer samples under 50 years of age. 
Loss of MLH1 or MSH2 protein expression in
tumour tissue, due to mutation and/or inactivation of
both copies of the gene involved, can be detected by
immunohistochemistry (IHC), using commercially
available antibodies. IHC for MLH1 and MSH2 proteins
has a high sensitivity and predictive value in detecting
MMR deficient cancers and therefore offers an
alternative strategy for selecting HNPCC families [19,
20]. IHC can suggest the presence of a mutation within
a specific MMR-encoding gene and therefore directs
germline mutation analysis to a single potentially
affected gene, saving unnecessary mutation analysis. 
The aim of this study was to determine the most
cost-effective strategy for the detection of MMR gene




Pedigree and clinical data were collected for a series
of 138 families referred to our regional genetics service
between 1996 and 2002. Our guidelines for referral
were equivalent to the Bethesda guidelines. We classified
each pedigree for the purposes of this analysis using the
established clinical criteria (Amsterdam, Amsterdam II,
Modified Amsterdam criteria and Bethesda guidelines).
DNA extracted from peripheral white blood cells (PBLs)
from a single proband in each family was used for
mutation analysis. Tumour blocks were requested for all
cases but material for only 55 cases was available. 
Immunohistochemistry
For each sample, eight sections (3-4 µm) were cut
and mounted onto glass slides. After dewaxing and
rehydration of sections, antigenic site retrieval was
accomplished by microwaving each slide for five minutes
in 0.01 M citric acid buffer (pH 6.0). Endogenous
peroxidase activity was blocked by incubation with 2%
hydrogen peroxide for 20 minutes and non-specific
binding prevented by incubation with 1% bovine serum
albumin (BSA) in phosphate buffered saline (PBS). Sections
were subsequently incubated with either monoclonal anti-
MLH1 or anti-MSH2 antibodies (Oncogene, Cambridge,
Massachusetts, USA) for two hours at room temperature.
Antibody binding was detected using the Ellite Vectastain
ABC kit (Vector Laboratories Ltd, Peterborough, UK), using
the manufacturer’s protocol. The reaction was visualised
using a VIP substrate kit for peroxidase (Vector
Laboratories Ltd). Sections were then dehydrated and
mounted. Normal colonic crypt epithelium taken from
tissue adjacent to the tumour served as an internal positive
control. In almost all cases, staining was observed in only
some areas of the tumour or control sections. Loss of
expression was recorded when nuclear protein expression
was observed in normal tissues and tumour-associated
stroma but not within malignant epithelial cells (i.e.
carcinoma cells). Examples are shown in Fig. 1. 
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Microsatellite instability (MSI) 
Tumour DNA samples obtained from paraffin sections
were analysed for MSI using the BAT26 marker. Six (5
µm) thick tissue sections were dewaxed and dried to form
a pellet which was then processed according to the tissue
protocol (QIAamp DNA mini kit handbook – Qiagen)
to yield DNA. PCR amplification was carried out in a 25
µl reaction volume containing 50-100 ng of genomic
DNA, 10 x PCR buffer, 0.2 mM dNTPs (Promega), 0.2
µM each primer, and 0.5 units of Hotstar taq polymerase
(Qiagen). The final MgCl2 concentration was 2.5 mM.
[PCR cycles: 95°C for 15 minutes, 35 cycles at 94°C for
30 seconds, 50°C for 30 seconds and 72°C for 30
seconds, followed by 72°C for 7 minutes and finally 60°C
for 60 minutes]. PCR products were run on an ABI 3100
genetic analyser (Applied Biosystems Perkin Elmer).
Microsatellite instability was defined as the presence of
altered allele sizes in the PCR-amplified product of tumour
DNA compared with the PCR-amplified product from the
genomic DNA sample of the same individual. 
Mutation analysis
DNA was extracted from PBLs using standard
techniques. Genomic DNA (100ng) was amplified
using a combination of the primers and conditions
listed by Holinski-Feder et al [21] as well as some
primers designed in house. Initially heteroduplex
analysis was used and subsequently superseded by
dHPLC. MLPA were used in the remaining cases where
a pathogenic mutation had not already been detected. 
PCR amplification and heteroduplex formation
PCR reactions were carried out in a total volume of
25 µl: each reaction contained 2.5 µl Gene Amp 10x
Buffer II (no MgCl2), 2.5 µl 25 mM MgCl2, 2.5 µl of
2 mM dNTP mix, 0.1 µl of AmpliTaq GoldTM (PE Applied
Biosystems, Foster City, California, USA), 10.4 µl sterile
distilled water, 1.0 µl of each 10 nM primer and 50 ng
of DNA. [PCR cycles: 95°C for 15 minutes, 35 cycles
consisting of 95°C denaturation for 30 seconds,
annealing at 53°C or 60°C for 45 seconds, and
extension at 72°C for 45 seconds, followed by a final
extension at 72°C for 7 minutes]. Prior to analysis the
PCR products were heteroduplexed at 95°C for 5 minutes
with a reduction of 1.5°C per cycle for 45 cycles. 
Heteroduplex analysis
10 µl of PCR product was run overnight on a 24
cm Hydrolink gel (AT Biochem). Heteroduplex bands
were visualized by ethidium bromide staining. 
dHPLC analysis
The Transgenomic Wave® DNA Fragment Analysis
System (Transgenomic Inc, San Jose, California, USA)
was used for the DHPLC analysis. This included a DNA
Sep® polystyrene-divinyl benzene C18 column as the
stationary phase, and a mobile phase consisting of (A)
0.1 M Triethylammonium acetate (TEAA) and (B) 0.1
M TEAA-25% Acetonitrile (ACN) and a UV detector set
at 260 nm. The products were analysed using a range
of partial denaturing temperatures established using
Transgenomic Wave maker software version 3.4, with
a flow rate of 0.9 ml/min and linear gradients of B
increasing by 2% per minute. 
Multiplex Ligation Probe Assay
Multiplex Ligation Probe Assay (MLPA) was
performed using kit P003 from MRC-Holland
(Amsterdam, The Netherlands). MLPA PCR products
were separated on an ABI 3100 machine and analysed
using Genotyper version 2.0 (Perkin-Elmer). Peak
heights from each patient were then compared to those
of normal control individuals using an Excel spreadsheet
to assess the ratios of each test peak relative to the
corresponding peaks in the control patients. 
Sequence analysis
PCR products were sequenced in forward and reverse
directions using BigDye® Terminator v1.1 chemistry
(Applied Biosystems). Samples underwent 25 cycles of
amplification (30 seconds at 96°C, 15 seconds at 50°C,
2 minutes at 60°C). Excess terminators were removed
using DyeExTM 2.0 spin columns (Qiagen) prior to running
on an ABI 3100 genetic analyser. 
Statistical analysis
The sensitivity and specificity for each set of clinical
criteria as a means of identifying families with an
inherited MMR-encoding gene mutation were calculated
using 2x2 tables. The sensitivity of each set of criteria
was defined as the proportion of patients with a mutation
in MLH1 or MSH2 who met those clinical criteria i.e.
those who would be ”correctly” selected for mutation
testing using these clinical criteria (sensitivity [%] = true
positives/[true positives + false negatives] x 100). The
specificity of each set of criteria was defined as the
proportion of patients who did not have a mutation in
MLH1 or MSH2 or who did not fulfil those clinical criteria
i.e. those who would be correctly excluded from
mutation testing using these criteria (specificity [%] =
true negatives/[true negatives + false positives] x 100).
Francesca Pigatto et al
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95% confidence intervals were calculated using StatXact
version 4 software (Cytel Software Corporation). The
predictive value of the clinical criteria was estimated
using the observation that the prevalence of gene
mutations in the whole target group is 49/138 (35.5%)
and gives a measure of the overall performance of each
of the criteria used for selection. 
Cost analysis – strategies examined
1. Clinical criteria only, full mutation analysis on both
MLH1 and MSH2 genes. 
2. Using IHC to determine which gene to test and testing
only the cases with abnormal protein expression. 
3. Using MSI testing followed by full mutation analysis
on both genes, where BAT26 was unstable. 
4. Using IHC then if normal (no loss) MSI analysis, then
mutation analysis if either result abnormal. 
The costs of the analyses used for the calculations
were based on charges in our diagnostic laboratories:
IHC – 50 euros, MSI – 50 euros (BAT26 only), Mutation
analysis – 500 euros per gene analysed. 
Results
A total of 138 families were included. 53 families
fulfilled the Amsterdam criteria, 65 fulfilled the Modified
Amsterdam criteria, 68 fulfilled Amsterdam II criteria
and 134 fulfilled the Bethesda guidelines. The search
for germline mutations in MLH1 and MSH2 was
performed initially using PCR amplification and
heteroduplex analysis; 133 patients subsequently
underwent dHPLC analysis. MLPA analysis was carried
out on 99 patients (including all cases where a mutation
had not been detected using the other techniques). 
The mutations found in the MLH1 and MSH2 genes
along with the results of MSI and IHC are summarised
in Tables 2a and 2b. 
Clearly deleterious mutations were found in 49 of
the 138 families (35.5%): 20 in MLH1 and 29 in MSH2
(18 frameshift, 10 nonsense, 9 splice site mutations,
7 large deletions and 5 missense mutations). For the
5 missense mutations, four had evidence of loss of MLH1
expression and for the fifth where tissue blocks were not
available, clear evidence of segregation of the mutation
with tumour predisposition was found. Additional six
families were found to have mutations of unclear
significance: 5 missense mutations and one inframe
deletion. Only clearly deleterious mutations were counted
for the purposes of this analysis. 
Sensitivity and specificity of clinical criteria (Table 3) 
The most sensitive criteria were the Bethesda criteria
1 to 3 (92%) but these criteria had relatively low
specificity at 39%. The small increase in sensitivity from
adding the Bethesda 4 to 7 criteria resulted in an overall
large reduction in specificity to 2%. The Amsterdam II
criteria performed well in this series for both sensitivity
(80%) and specificity (69%) with similar figures for
Amsterdam and modified Amsterdam categories. 
Mutation testing strategy analysis
Both IHC for MSH2 and MLH1 and MSI analysis
with the BAT26 marker were available in 55 of 138
patients. Pathogenic mutations were identified in 16/55
(29%). In further 4 cases, previously extracted pathology
DNA was available but not tumour blocks and in
9 cases we had IHC data but MSI analysis was
unsuccessful. Sensitivity for IHC was 84% (62% to 96%)
and for MSI was 68% (43% to 87%). 
Cost analysis
Proceeding directly to mutation analysis was the most
expensive option for all clinical criteria. IHC greatly
reduced the cost of mutation detection due to only
needing to analyse one of the two genes in cases with
an informative result (loss of protein expression). Three
mutations were missed out of twenty one mutations found
where IHC was tested, all of the missed mutations were
in the hMLH1 gene (clinical criteria were Amsterdam (1)
and Bethesda 1 to 3 (2)). MSI alone, using BAT26 as
the only marker of instability, had a lower ability
compared with IHC to predict the presence of
a mutation. Where both MSI and IHC data were
available the maximum sensitivity was gained with only
a modest increase in cost above that using IHC alone.
If only one technique were available, IHC would be more
cost effective than MSI analysis. Table 4 summarises the
cost analyses for the possible strategies considered. 
Discussion
Our study shows that by combining IHC and MSI
analysis with clinical criteria, the cost of mutation
detection can be reduced without lowering the mutation
detection rate. Our results have implications for routine
diagnostic genetics services where the capacity for
mutation testing is constrained by the rate of throughput
and available funding within a nationally funded health
care service. The proposed strategy requires that
tumour tissue is made freely available. 
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Table 2a. Detected MHL1 mutations, clinical criteria and results of MSI and IHC analyses
clinical colon colon MS loss loss mutation pathogenic MLH1
criteria cancer cancer status MLH1 MSH2 type mutation
total average age expression expression
A 4 46 ND Yes No missense yes 350C>T
A 3 34 MSI No No frameshift yes 1821insT
A ~7 NK* ND ND ND frameshift yes 11379-1380delAG
A 4 54 MSI ND ND stop yes 2135G>A
A 5 35 ND ND ND frameshift yes 1492insG
A 4 37 MSI Yes No stop yes 2250C>A
A 9 45 MSS Yes No missense yes 122A>G
A 3 35 ND ND ND frameshift yes 735delC
A 3 32 ND ND ND missense yes 199G>A
A 4 43 MSI ND ND stop yes 1459C>T
A 6 46 ND ND ND frameshift yes 105insAAA
A 3 54 MSI Yes No frameshift yes 2252-2253delAA
B1-3 2 61 MSI No No splice yes 1989+1G>A
B1-3 2 39 MSI Yes No missense yes 350C>T
B1-3 1 30 MSS No No missense NK 110A>G
B1-3 1 48 ND No No stop yes 2250C>A
B1-3 2 34 ND ND ND missense yes 350C>T
B1-3 1 62 ND ND ND stop yes 1849A>T
B4-7 1 28 MSI Yes No inframe NK 1854-1856delAAG
B4-7 1 35 MSI Yes No splice yes 588+1G>A
MA 2 42 ND No Yes missense** no 2125G>A
MA 2 45 ND ND ND missense NK 2041G>A
MA 3 59 ND ND ND splice yes 2104-1delGAG
MA 2 43 ND ND ND splice yes 677G>A
* extensive family history of colorectal cancer but no confirmatory details except for index case;
** a large deletion in hMSH2 was also found in this case
Syngal et al examined the performance of existing
clinical criteria for HNPCC in identifying and excluding
mutations in MSH2/MLH1 and found the Amsterdam
criteria to be insufficiently sensitive (61%) and specific
(67%) to be used as the sole criterion for identifying
which families should undergo genetic testing; as in
our study, increasing the sensitivity of criteria was
associated with reduced specificity [22]. 
Selection of cases using the Bethesda criteria should
be supplemented with further tumour based analyses as
described however there are a variety of possible barriers
to this approach including practical, ethical and technical
difficulties. Practical problems include retention of tissues
in pathology laboratories, method of preservation of
archival tissues, willingness of hospitals to locate and
release material and the current uncertainties (particularly
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Table 2b. Detected MSH2 mutations, clinical details and results of MSI and IHC analyses
clinical colon colon MS loss loss mutation pathogenic MSH2
criteria cancer cancer status MLH1 MSH2 type mutation
total average age expression expression
A 2 47 ND ND ND stop yes 1072G>T
A 4 46 ND ND ND frameshift yes 1578delC
A 3 53 ND ND ND frameshift yes 1577delC
A 3 46 MSI ND ND frameshift yes 2502-2508 del
A 3 40 ND ND ND frameshift yes 1059delG
A 3 46 ND ND ND frameshift yes 1986delAG
A 3 45 ND ND ND splice site mutation yes 942+3A>T
A 6 38 MSS No Yes splice site mutation yes 942+3A>T
A 8 45 ND ND ND stop yes 1165C>T
A 3 44 ND ND ND frameshift yes 2481delG
A 3 36 ND ND ND stop yes 351G>A
A 2 40 ND ND ND frameshift yes 526delC
A 3 50 ND ND ND large deletion yes exon 1del
A 3 49 MSS No Yes lge del yes exons 1-2del
A 3 57 ND ND ND missense NK 1760-62G>A
A 4 44 MSI No Yes frameshift yes 1218insTACCG
A 3 38 MSS No Yes lge del yes exons 9-16del
A 3 36 MSI No Yes lge del yes exons 4-16del
A 8 46 MSS No Yes frameshift yes 924delAG
A2 3 57 MSI No Yes frameshift yes 680-716 dup
A2 2 56 MSS No No missense polymorphism 965G>A
A2 2 47 ND ND ND stop yes 1072G>T
B1-3 2 23 MSI No Yes lge del yes exons 9-16del
B1-3 1 43 MSI No Yes missense NK 817G>A & 818T>A
B1-3 2 47 MSS No No missense polymorphism 2006-6T>C
B4-7 1 26 ND ND ND stop yes 1609A>T
B4-7 1 41 MSS No Yes large deletion yes exons 1-8del
MA 3 45 ND ND ND frameshift yes 2501-2507 del
MA 2 52 ND ND ND nonsense yes 2038C>T
MA 4 51 ND ND ND splice yes 943-1G>A
MA 3 70 ND ND ND frameshift yes 2634insT + delGGTTTGTCAG
MA 2 42 ND No Yes lge del yes exons4-16del
MA 2 47 ND ND ND splice mutation yes 942+3A>T
Abbreviations:
A – meets the full Amsterdam criteria; A2 – meets the Amsterdam 2 criteria; B – meets the Bethesda guidelines (1-3, 4-7); 
MA – meets the modified Amsterdam criteria; ND – not done; NK – not known
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Table 3. Sensitivity and specificity of clinical criteria for identifying kindreds with pathogenic MSH2 or MLH1 mutations
Clinical criteria Number No of families Families Sensitivity Specificity Positive
of families with MSH2 with mutations (95% confidence (95% confidence predictive value
fulfilling or MLH1 missed intervals) intervals) (95% confidence
criteria mutations by criteria intervals)
Amsterdam 53 30 19 61% (46-74%) 74%  (65-82%) 57% (43-69%)
Modified Amsterdam 65 37 12 76% (62-87%) 69% (58-78%) 57% (45-68%)
Amsterdam II 67 39 10 80% (66-90%) 69% (58-78%) 58% (46-69%)
Bethesda 1-3 99 45 4 92% (81-97%) 39% (30-50%) 46% (36-55%)
Bethesda all 136 49 0 100% (93-100%) 2% (0-7%) 36% (28-44%)
at this time in the UK) about consent. These were all
barriers we experienced in retrieving suitable tissue for
this study. Technically MSI analysis involves DNA
extraction from archival paraffin-embedded blocks which
is labour-intensive and time-consuming and yields
variable quality. We chose to use a single, reportedly
highly sensitive monoallelic repeat marker for instability
testing because the costs were equivalent to the cost of
performing immunohistochemistry. However our data
show that the sensitivity of BAT26 alone is disappointing
and future work using the currently recommended panel
of markers would be likely to improve sensitivity [11]. 
Immunohistochemistry is relatively inexpensive and
easy to perform on paraffin blocks. One disadvantage
of IHC is that not all laboratories achieve robust and
reproducible results so it may not be an option in every
centre [23]. Also, IHC cannot achieve 100% sensitivity
in the detection of mutations because of the occurrence
of some types of mutation may lead to a non-functional
protein but retention of the antigen binding epitopes.
However an important advantage of IHC over MSI
analysis is to indicate which MMR gene should be
analysed for a germline mutation. The ability to compare
tumour nuclear staining with stromal tissue and adjacent
non-neoplastic tissue in all cases provides a robust
internal control for comparisons. Recent work has
highlighted the importance of extending IHC analysis to
include MSH6 and PMS2 [24]. Although these were not
included in this analysis, we would anticipate that
inclusion of these would improve mutation detection
without greatly increasing the cost of analysis. 
Previous studies have examined the use of IHC in
tumours associated with MMR gene defects. Lindor et
al compared MSI analysis with IHC detection of MLH1
and MSH2 in 1144 colorectal cancers and found that
IHC provided a sensitive (92.3%) and specific (100%)
method for predicting the presence of MSI but germline
mutations in DNA mismatch repair genes were not
looked at [25]. 
Debniak et al evaluated the significance of
pedigree/clinical data, IHC and MSI analysis in
reducing the cost of determining MLH1/MHS2 gene
mutations in 25 patients with colorectal cancer. They
found that the greatest reduction of costs in the
detection of one mutation was achieved when genetic
testing was limited to the evaluation of pedigree/clinical
data and IHC, although in such a diagnostic model
some mutations can be missed [26]. Our data agree
with the conclusions of these authors. 
In summary, the results of our study indicate that the
strategy achieving the highest sensitivity for the lowest
cost in the identification of MLH1 and MSH2 germline
mutations is to use sensitive clinical criteria followed by
IHC on tumour blocks and when this is normal, MSI
analysis. If tumour tissue is not available, it is more cost
effective to use more stringent clinical criteria such as the
Modified Amsterdam criteria. The availability of tumour
tissue blocks and experience in the diagnostic laboratory
in these additional tumour based tests can maximise cost
effectiveness of mutation searching in HNPCC. 
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